Stocks › RGNX
REGENXBIO Inc.
RGNX·Nasdaq·
United States·USD
United States·USD$7.45
-0.31 (-3.99%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
RGNX
REGENXBIO Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RGNXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of RGNX by members of U.S. Congress · 2 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Peter WelchHouse · D · VT |
RGNXREGENXBIO Inc. · Stock |
Purchase $1,001 - $15,000 |
Nov 14, 2019 | Oct 22, 2019 | Filing ↗ |
| Peter WelchHouse · D · VT |
RGNXREGENXBIO Inc. · Stock |
Sale $1,001 - $15,000 |
Nov 14, 2019 | Nov 8, 2019 | Filing ↗ |
Whale Activity
Position changes in RGNX reported for 2026-06-30 by 10 tracked institutional filers
- Increased6
- New1
- Held0
- Decreased1
- Closed1
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 6.4M | $76.6M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $25.2M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.4M | $16.2M | increased |
| D. E. Shaw & Co., Inc. | 712.8K | $8.5M | increased |
| TWO SIGMA INVESTMENTS, LP | 669.8K | $8.0M | increased |
| CITADEL ADVISORS LLC | 669.0K | $8.0M | new |
| MILLENNIUM MANAGEMENT LLC | 480.8K | $5.8M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 256.7K | $3.1M | decreased |
| ArchPoint Investors | 222.3K | $2.7M | — |
| Point72 Asset Management | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by RGNX insiders, by quarter · Form 4
Recent Insider Transactions
756 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Ciongoli Gregory AustinDirector · Director | Purchase | +53.4K | $9.36 | $500K | Aug 27, 2026 | Form 4 ↗ |
| Ciongoli Gregory AustinDirector · Director | Purchase | +49.2K | $9.14 | $450K | Aug 26, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Sale | −2,161 | $13.64 | $29K | Jul 2, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Sale | −36.7K | $12.86 | $472K | Jul 1, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Sale | −19.6K | $11.04 | $216K | Jun 29, 2026 | Form 4 ↗ |
| Bennett JeanDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Zachary JenniferDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Glucksmann AlexandraDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Fox Allan M.Director | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Mills Kenneth T.Director | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Tasse DanielDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| STUMP DAVID CDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| KARABELAS ARGERIS NDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| MIGAUSKY GEORGE VDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Sale | −15.3K | $11.02 | $169K | May 11, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Sale | −5,124 | $10.35 | $53K | Mar 10, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Tax withholding | −5,267 | $11.16 | $59K | Feb 1, 2026 | Form 4 ↗ |
| Christmas Patrick J.Chief Strategy & Legal Officer | Tax withholding | −4,700 | $11.16 | $52K | Feb 1, 2026 | Form 4 ↗ |
| Mills Kenneth T.Director | Tax withholding | −221.8K | $13.41 | $3.0M | Jan 27, 2026 | Form 4 ↗ |
| Mills Kenneth T.Director | Option exercise | +225.0K | $13.09 | $2.9M | Jan 27, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding RGNX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 2.0M | $23.5M | 0.22% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.5M | $17.9M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.3M | $15.2M | 0.02% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund TIAA-CREF Funds | 855.2K | $8.3M | 0.20% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund JPMorgan Trust II | 629.8K | $7.5M | 0.29% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 564.5K | $6.8M | 0.01% | Jun 30, 2026 |
| VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS | 467.2K | $5.6M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 527.9K | $5.1M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 378.1K | $4.5M | 0.03% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 336.2K | $4.0M | 0.04% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list RGNX's shares (CUSIP 75901B107), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming regenxbio as client
- THEGROUP DC, LLCREGENXBIO · 2026 Q2 · HCR$60K
Filing ↗ - DLA PIPER LLP (US)REGENXBIO INC. · 2026 Q2 · HCR, MED$60K
Filing ↗ - LMH STRATEGIC SOLUTIONSREGENXBIO INC. · 2026 Q2 · HCR, PHA$60K
Filing ↗ - THEGROUP DC, LLCREGENXBIO · 2026 Q1 · HCR$60K
Filing ↗ - LMH STRATEGIC SOLUTIONSREGENXBIO INC. · 2026 Q1 · PHA, HCR$60K
Filing ↗
Government Contracts
Federal awards to REGENXBIO Inc. · USAspending
No federal contract awards found for REGENXBIO Inc..
U.S. Patents
Recent USPTO applications naming REGENXBIO Inc.
No USPTO patent applications found for REGENXBIO Inc..
Annual Financials
From RGNX's 10-K filings · XBRL
No annual XBRL figures on record for RGNX. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in RGNX's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01Material agreementSep 23, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeAug 25, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsAug 24, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJul 20, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 29, 2026
EDGAR ↗ - 8-K · Items 5.07, 8.01Shareholder vote · Other eventsJun 3, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 8.01, 9.01Results of operations · Reg FD disclosure · Other eventsMay 14, 2026
EDGAR ↗
About REGENXBIO Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersROCKVILLE, MD
SEC CIK0001590877 ↗
Former namesReGenX Biosciences, LLC